Basic information Supplier

Sobuzoxane

Basic information Supplier
98631-95-9 Basic informationMore
USE
Sobuzoxane, a novel bis(2,6-dioxopiperazine) derivative, was introduced in Japan for the treatment of malignant lymphoma and adult T-cell IeukemiaQmphoma (ATLL), which is resistant to chemotherapy and has a poor prognosis. Sobuzoxane exhibits 8 broad spectrum of antitumor activity. It is a noncleavable complexstabilizing topoisomerase II inhibitor and exerts its function via interfering with the catalytic activity of the enzyme to result in an irreversible inhibition of cell division by blockade of chromosome condensation and segregation. Due to Its unique mode of cytocidai activity, it has no cross resistance with many currently available anticancer agents. Sobuzoxane is reported to significantly inhibit growth of human colon, lung, gastric, and breast cancers and is in clinical trials for these indications.

Browse by Nationality 98631-95-9 Suppliers >Global suppliers

Chongqing (1) Guangdong (1) Zhejiang (1) Hubei (1) Jiangsu (1) Member (3) All (5)
Please select the suppliers
Recommend You Select Member Companies
  • Company Name:CONIER CHEM AND PHARMA LIMITED
  • Tel: +8618523575427
  • Products Intro:Product Name:sobuzoxane
    CAS:98631-95-9
    Purity:0.99 Package:1kg
  • CB Index:58
  • Related Information:Catalog(49392)
  •  
  • Company Name:Nantong QuanYi Biotechnology Co., Ltd
  • Tel:0513-66337626 18051384581
  • Products Intro:Product Name:Sobuzoxane/MST 16
    CAS:98631-95-9
    Purity:98%+ HPLC Package:10mg,100mg,500mg,1g,2g,5g,10g,More
  • CB Index:58
  • Related Information:Catalog(4738)
  •